GABA-A modulation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
All nanotubes are expected to be very good thermal conductors along the tube, exhibiting a property known as "ballistic conduction", but good insulators lateral to the tube axis. Measurements show that an individual SWNT has a room-temperature thermal conductivity along its axis of about 3500 W·m−1·K−1; compare this to copper, a metal well known for its good thermal conductivity, which transmits 385 W·m−1·K−1. An individual SWNT has a room-temperature thermal conductivity lateral to its axis (in the radial direction) of about 1.52 W·m−1·K−1, which is about as thermally conductive as soil. Macroscopic assemblies of nanotubes such as films or fibres have reached up to 1500 W·m−1·K−1 so far. Networks composed of nanotubes demonstrate different values of thermal conductivity, from the level of thermal insulation with the thermal conductivity of 0.1 W·m−1·K−1 to such high values. That is dependent on the amount of contribution to the thermal resistance of the system caused by the presence of impurities, misalignments and other factors. The temperature stability of carbon nanotubes is estimated to be up to 2800 °C in vacuum and about 750 °C in air. Crystallographic defects strongly affect the tube's thermal properties. Such defects lead to phonon scattering, which in turn increases the relaxation rate of the phonons. This reduces the mean free path and reduces the thermal conductivity of nanotube structures. Phonon transport simulations indicate that substitutional defects such as nitrogen or boron will primarily lead to the scattering of high-frequency optical phonons.
In Donetsk Oblast, Russian forces claimed to have taken control of the villages of Novooleksandrivka, northwest of Ocheretyne, and Spirne, near the border with Luhansk Oblast. One person was killed in a Russian airstrike in Kharkiv. The Russian defence ministry claimed to have shot down 36 Ukrainian drones, including two over Belgorod Oblast, four over Voronezh Oblast, nine over Lipetsk Oblast and two both over Oryol Oblast and Belgorod Oblasts. Fifteen drones were also downed over Kursk Oblast. There were no reports of damage or casualties.
== History == In 1994 Tsutomu Nomizu and colleagues at Nagoya University performed the first mass spectrometry experiments of single cells. Nomizu realized that single cells could be nebulized, dried, and ignited in plasma to generate clouds of ions which could be detected by emission spectrometry. In this type of experiment elements such as calcium within the cell could be quantified. Inspired by Flow cytometry, in 2007 Scott D. Tanner built upon this ICP-MS with the first multiplexed assay using lanthanide metals to label DNA and cell surface markers. In 2008 Tanner described the tandem attachment of a flow cytometer to an ICP-MS instrument as well as new antibody tags that would allow massively multiplexed analysis of cell markers. By further optimizing the detection speed and sensitivity of this flow coupled to ICP-MS they built the first CyTOF instrument. The CyTOF instrument was originally owned by the Canadian company DVS Sciences but is now the exclusive product of Fluidigm after their acquisition in 2014 of DVS sciences. In 2022 Fluidigm received a capital infusion and changed its name to Standard BioTools. There have been 4 iterations of the CyTOF apparatus named CyTOF, CyTOF2, Helios™ and CyTOF XT. The successive improvements were largely in increased detection range and software parameters with the Helios instrument able to detect from metals ranging from yttrium-89 to bismuth-209 and throughput and analyze 2000 events per minute.
=== Pharmacokinetics === Pharmacokinetic data collected from animal studies performed in mice and rats revealed an oral Tmax of 15 minutes, an area under the curve of 2.943 mg·hr·L−1, and an elimination half-life of 1.3 hours. Pharmacokinetic testing has been able to help explain the longer acting pharmacologic effects of osemozotan as well as its increased potency. Osemozotan was shown to have increased duration of pharmacologic effects compared to azapirones and requires a substantially lower dose to produce its pharmacologic effects. This result suggests that patients may not have to take the medication as often throughout the day. In these studies, there was a difference in dosage amount required for the intended indication. Osemozotan does not metabolize to 1-(2-pyrimidinyl)-piperazine (1-PP), a common metabolite found with the azapirone class of medications that has affinity for receptors other than the 5-HT1A receptor, thus decreasing its specificity and increasing the risk of unwanted effects. Since osemozotan does not produce this metabolite, it has greater specificity toward the 5-HT1A receptor when compared to other anxiolytic medications.
Sources: en.wikipedia.org
A Bitubale is baled asphalt, in cold form, wrapped in white plastic or in asphalt-based film. Invented by Singapore-based Eastern Petroleum Group, Bitubale is a green technology innovation for the global bitumen (asphalt) transport supply chain. Bitubales are produced in specially designed plants for cooling, dispensing, encapsulation, and packing of bitumen at its supply source. The technologies support cold-form transport of bitumen with zero waste at the end of its supply chain. Primary benefits of the Bitubale, over hot-form transported asphalt, are halving of the CO2 emissions across the bitumen transport supply chain, large increases in workplace safety for bitumen/asphalt transport workers, elimination of long-term health risks from bitumen/asphalt fumes for transportation workers, elimination of accidental pollution of environmental assets during asphalt transport, and elimination of polluting bitumen-residue waste in millions of discarded drums in landfills.
== Fusion lineage == The formation of all syncytiotrophoblast is from the fusion of two or more cytotrophoblasts via this fusion pathway. This pathway is important because the syncytiotrophoblast plays an important role in fetal-maternal gas exchange, nutrient exchange, and immunological and metabolic functions. An undifferentiated cytotrophoblastic stem cell will differentiate into a villous cytotrophoblast, which is what constitutes primary chorionic villi, and will eventually coalesce into villous syncytiotrophoblast. The formation of syncytiotrophoblast from cytotrophoblast is a terminal differentiation step of trophoblastic cells. Syncytialization of cytotrophoblastic cells can be induced in vitro through multiple signalling molecules including epidermal growth factor, glucocorticoids, and human chorionic gonadotropin.
Portal received critical acclaim, often earning more praise than either Half-Life 2: Episode Two or Team Fortress 2, two titles also included in The Orange Box. It was praised for its unique gameplay and dark, deadpan humor. Eurogamer cited that "the way the game progresses from being a simple set of perfunctory tasks to a full-on part of the Half-Life story is absolute genius", while GameSpy noted, "What Portal lacks in length, it more than makes up for in exhilaration." The game was criticized for sparse environments, and both criticized and praised for its short length. Aggregate reviews for the standalone PC version of Portal gave the game a 90/100 through 28 reviews on Metacritic. In 2011, Valve stated that Portal had sold more than four million copies through the retail versions, including the standalone game and The Orange Box, and from the Xbox Live Arcade version. The game generated a fan following for the Weighted Companion Cube—even though the cube itself does not talk or act in the game. Fans have created plush and papercraft versions of the cube and the various turrets, as well as PC case mods and models of the Portal cake and portal gun. Jeep Barnett, a programmer for Portal, noted that players have told Valve that they had found it more emotional to incinerate the Weighted Companion Cube than to harm one of the "Little Sisters" from BioShock.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.